Table 3.

Multivariate analysis: risk factors for ACA/SCD among LQT2 patients by gender^*†

	LQT2 Males		LQT2 Females
	HR (95% CI)	P-Value	HR (95% CI)	P-Value
Mutation-Location
Pore-loop vs. nonpore-loop	2.18 (1.28 – 3. 72)	0.01	1.20 (0.83 – 1.74)	0.33
Pore-loop vs. C/N-term	2.04 (1.15 – 3.61)	0.01	1.18 (0.81 – 1.70)	0.39
TM (nonpore) vs. C/N-term	NA‡		1.25 (0.60 – 2.58)	0.56
Mutation-Type
Missense vs. non-missense	0.56 (0.29 – 1.06)	0.08	1.29 (0.82 – 1.74)	0.25
QTc duration (msec)
≥500 vs. <500	2.16 (1.08 – 5.06)	0.03	4.05 (2.33 – 7.04)	<0.001
Time-Dependent Syncope
Syncope vs. no syncope	2.83 (1.36 – 5.58)	0.01	3.32 (2.19 – 4.87)	<0.001

^*Findings were further adjusted for missing QTc values, time-dependent β-blocker therapy, and the occurrence of syncope prior to the end point (assessed as a time-dependent covariate)

^†Models were carried out in the total population using interaction-term analysis, with interactions tested one at a time; all interaction p-values were >0.05.

^‡Hazard ratio was not computed due to a low event rate in male patients with TM mutations.

ACA = aborted cardiac arrest; LQT2 = long QT syndrome type 2; SCD = sudden cardiac death; TM = transmembrane.